Abstract:Background Honokiol (HNK), a natural phenolic compound derived from Magnolia plants, exhibits therapeutic effects on various diseases, including cancer. The advent of immune checkpoint inhibitors (ICIs) has marked a breakthrough in non-small cell lung cancer (NSCLC) treatment. However, a significant subset of patients exhibits primary or acquired resistance to anti-PD-1/PD-L1 therapies, necessitating the development of novel combination strategies to enhance therapeutic efficacy and overcome resistance. Purpose This study aimed to explore the anti-tumor efficacy of liposomal honokiol (Lipo-HNK) and elucidate the synergistic effects of Lipo-HNK and ICIs on NSCLC. Methods The effects of Lipo-HNK on cell proliferation and apoptosis were assessed in human lung cancer cell lines H460 and A549, and mouse Lewis lung cancer cell line (LL2). A murine lung cancer model was established by injecting LL2 cells via the tail vein to evaluate the therapeutic effects of Lipo-HNK and ICIs. Tumor microenvironment features were characterized using immunofluorescence and flow cytometry. Primary macrophages were extracted from mouse bone marrow for mechanistic studies. High-throughput sequencing and bioinformatics analyses of Lipo-HNK-treated macrophages were conducted to identify key signaling pathways, which were subsequently confirmed by Western blotting and inhibitor blockade. Results Lipo-HNK, with enhanced solubility and bioavailability, demonstrated potent cytotoxicity against NSCLC cell lines. In the murine lung cancer model, Lipo-HNK exhibited synergistic anti-cancer effects when combined with anti-PD-1 therapy. Immunofluorescence and flow cytometry analyses revealed that Lipo-HNK significantly reduced the infiltration of myeloid-derived suppressor cells (MDSCs) and M2 macrophages (CD206+). Macrophage depletion experiment showed the anti-tumor effects of Lipo-HNK was macrophage-dependent. M2 macrophages induced by tumor-conditioned medium (TCM) or interleukin-4 (IL-4) released immunosuppressive cytokines such as IL-10, Arg-1, and TGF-β. RNA sequencing analyses showed that Lipo-HNK effectively inhibited the PI3K/Akt signaling pathway, blocking macrophage polarization to the M2 type. Furthermore, the combination of Lipo-HNK and anti-PD-1 therapy led to increased CD8+ T-cell infiltration and activation, enhancing the overall anti-tumor immune response. Conclusion This study validated the anti-tumor efficacy of Lipo-HNK against NSCLC. Lipo-HNK reduced the infiltration of MDSCs and M2 macrophages by inhibiting the PI3K/Akt pathway and enhanced the therapeutic effects of ICIs. These findings provide evidence and new insights into Lipo-HNK as a promising anti-cancer drug for NSCLC treatment, highlighting its potential to overcome resistance to current ICI therapies.

Honokiol Exhibits Anti-Tumor Effects in Breast Cancer by Modulating the miR-148a-5p-CYP1B1 Axis

PUB045 Anti-Tumor Effect of Honokiol in Lung Squamous Cell Carcinoma

Honokiol Induces Apoptosis and Autophagy Via the ROS/ERK1/2 Signaling Pathway in Human Osteosarcoma Cells in Vitro and in Vivo.

Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation

Honokiol regulates ovarian cancer cell malignant behavior through YAP/TAZ pathway modulation

Honokiol Induces Ferroptosis In Colon Cancer Cells By Regulating Gpx4 Activity

Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway

Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth

Comprehensive Computational Analysis of Honokiol Targets for Cell Cycle Inhibition and Immunotherapy in Metastatic Breast Cancer Stem Cells

Honokiol Augments the Anti-Cancer Effects of Oxaliplatin in Colon Cancer Cells

Mechanism of Apoptotic Induction on T24 Cells by Honokiol and Its Synergistic Anticancer Effect in Combination with Hydroxycamptothecin

Honokiol: a Promising Small Molecular Weight Natural Agent for the Growth Inhibition of Oral Squamous Cell Carcinoma Cells.

Synergistic Antitumor Effects of Liposomal Honokiol Combined with Adriamycin in Breast Cancer Models.

Honokiol Prevents Lung Metastasis of Triple-Negative Breast Cancer by Regulating Polarization and Recruitment of Macrophages.

Honokiol inhibits interleukin-induced angiogenesis in the NSCLC microenvironment through the NF-κB signaling pathway

Commiphora myrrha n-hexane extract suppressed breast cancer progression through induction of G0/G1 phase arrest and apoptotic cell death by inhibiting the Cyclin D1/CDK4-Rb signaling pathway

Improved Therapeutic Effectiveness by Combining Liposomal Honokiol with Cisplatin in Lung Cancer Model

Honokiol Inhibits Bladder Tumor Growth by Suppressing EZH2/miR-143 Axis

Revealing the molecular mechanism of baohuoside I for the treatment of breast cancer based on network pharmacology and molecular docking

Liposomal Honokiol Inhibits Non-Small Cell Lung Cancer Progression and Enhances PD-1 Blockade Via Suppressing M2 Macrophages Polarization

Honokiol inhibits the growth of hormone-resistant breast cancer cells: its promising effect in combination with metformin